A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis

被引：99

作者：

Hu, Miaofen G. ^{[1
]}

Deshpande, Amit ^{[4
]}

Enos, Miriam ^{[1
]}

Mao, Daqin ^{[1
]}

Hinds, Elisabeth A. ^{[1
]}

Hu, Guo-fu ^{[2
]}

Chang, Rui ^{[1
,3
]}

Guo, Zhuyan ^{[1
,5
]}

Dose, Marei ^{[1
,6
]}

Mao, Changchuin ^{[1
]}

Tsichlis, Philip N. ^{[1
]}

Gounari, Fotini ^{[1
,6
]}

Hinds, Philip W. ^{[1
]}

机构：

[1] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA

[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA

[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA

[4] Univ Calif Los Angeles, Dent Res Inst, Los Angeles, CA 90024 USA

[5] MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA

[6] Univ Chicago, Dept Med, Comm Immunol, Chicago, IL 60637 USA

来源：

CANCER RESEARCH | 2009年 / 69卷 / 03期

关键词：

T-CELL DEVELOPMENT; SIGNALING PATHWAY; GENE-EXPRESSION; NOTCH; INDUCTION; INSULIN; LINEAGE; CDK6; FATE; SUPPRESSION;

D O I：

10.1158/0008-5472.CAN-08-2473

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cyclin-dependent kinase 6 (CDK6) promotes cell cycle progression and is overexpressed in human lymphoid malignancies. To determine the role of CDK6 in development and tumorigenesis, we generated and analyzed knockout mice. Cdk6-deficient mice show pronounced thymic atrophy due to reduced proliferative fractions and concomitant transitional blocks in the double-negative stages. Using the OP9-DL1 system to deliver temporally controlled Notch receptor-dependent signaling, we show that CDK6 is required for Notch-dependent survival, proliferation, and differentiation. Furthermore, CDK6-deficient mice were resistant to lympho-magenesis induced by active Akt, a downstream target of Notch signaling. These results show a critical requirement for CDK6 in Notch/Akt-dependent T-cell development and tumorigenesis and strongly support CDK6 as a specific therapeutic target in human lymphoid malignancies. [Cancer Res 2009; 69(3):810-8]

引用

页码：810 / 818

页数：9

共 50 条

[41] Flavopiridol, a cyclin-dependent kinase inhibitor
Lansiaux, A
Bailly, C
BULLETIN DU CANCER, 2000, 87 (10) : 697 - 701
[42] Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates
Mart Loog
David O. Morgan
Nature, 2005, 434 : 104 - 108
[43] Novel cyclin-dependent kinase inhibitors
Westwell, AD
DRUG DISCOVERY TODAY, 2001, 6 (13) : 701 - 701
[44] INHIBITORS OF CYCLIN-DEPENDENT KINASE AND CANCER
BIGGS, JR
KRAFT, AS
JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (10): : 509 - 514
[45] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
Grison, Alice
Atanasoski, Suzana
MOLECULAR NEUROBIOLOGY, 2020, 57 (07) : 3206 - 3218
[46] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
Alice Grison
Suzana Atanasoski
Molecular Neurobiology, 2020, 57 : 3206 - 3218
[47] Cyclin-dependent kinase inhibitors and hepatocarcinogenesis
Hui, AM
Sakamoto, M
Kanai, Y
Ino, Y
Gotoh, M
Hirohashi, S
RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 481 - 485
[48] Differential requirement of cyclin-dependent kinase 2 for oligodendrocyte progenitor cell proliferation and differentiation
Caillava, Celine
Baron-Van Evercooren, Anne
CELL DIVISION, 2012, 7
[49] Differential requirement of cyclin-dependent kinase 2 for oligodendrocyte progenitor cell proliferation and differentiation
Céline Caillava
Anne Baron-Van Evercooren
Cell Division, 7
[50] Overexpression of cyclin E and cyclin-dependent kinase 2 is correlated with development of hepatocellular carcinomas
Kohzato, N
Dong, YY
Sui, L
Masaki, T
Nagahata, S
Nishioka, M
Konishi, R
Tokuda, M
HEPATOLOGY RESEARCH, 2001, 21 (01) : 27 - 39

← 1 2 3 4 5 →